Product image of Granisetron Torrent Pharma (Uk) (Granisetron) supplied by GNH India

Granisetron Torrent Pharma (Uk)

Active Ingredient:
Granisetron
Origin:
EU

Granisetron Torrent Pharma (Uk) (Granisetron)

Granisetron Torrent Pharma (Uk) is a prescription intravenous formulation containing the active ingredient granisetron. It is classified as a 5‑HT3 receptor antagonist and is used as an antiemetic. The product is marketed in the European Union and is supplied only with a prescription. It is administered by healthcare professionals under controlled conditions.

Manufacturer / TM Owner

Torrent Pharma (Uk) Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Torrent Pharma (Uk) is indicated for the prevention of nausea and vomiting associated with specific medical procedures. It is commonly employed in oncology and surgical settings to improve patient comfort.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV)
  • Prevention of postoperative nausea and vomiting (PONV)
  • Adjunct therapy for radiation‑induced nausea
  • Use in patients at high risk for emesis due to emetogenic agents
  • Supportive care in hospice settings where nausea control is needed

Side Effects

Granisetron may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common

  • Headache
  • Constipation
  • Dizziness or light‑headedness
  • Fatigue or weakness
  • Diarrhoea
  • Abdominal discomfort

Serious

  • Allergic reactions such as rash, itching, or swelling
  • QT‑interval prolongation leading to cardiac arrhythmias
  • Severe hypotension or syncope
  • Anaphylaxis
  • Serotonin syndrome when combined with serotonergic agents

Precautions & Warnings

Before initiating Granisetron Torrent Pharma (Uk), clinicians should evaluate patient‑specific factors that may influence safety and efficacy. The following precautions are recommended:

  • Assess cardiac history, especially QT‑interval abnormalities
  • Review electrolyte status (potassium, magnesium, calcium) and correct imbalances
  • Use caution in patients with hepatic or renal impairment; dose adjustment may be required
  • Consider potential risks in pregnant or breastfeeding women; data are limited
  • Monitor for signs of hypersensitivity during and after infusion
  • Evaluate concomitant use of other anti‑emetic agents to avoid overlapping toxicity

Avoid Interactions

Granisetron can interact with several drug classes, affecting its safety profile or therapeutic effect. Awareness of these interactions helps optimize patient care.

Avoid

  • Other QT‑prolonging medications (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics)
  • Concurrent use of other 5‑HT3 antagonists
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase granisetron levels

Use with caution

  • CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce efficacy
  • Opioid analgesics that can also cause nausea or constipation
  • General anaesthetics and muscle relaxants used during surgery
  • Other serotonergic drugs that could predispose to serotonin syndrome

Frequently Asked Questions

Granisetron selectively blocks serotonin 5‑HT3 receptors in the central and peripheral nervous system, interrupting the signaling pathway that triggers nausea and vomiting.

It is prescribed for patients undergoing chemotherapy or surgery who are at risk of nausea and vomiting, as well as for those receiving radiation therapy with emetogenic potential.

The medication is given intravenously by a healthcare professional, usually as a single infusion before the emetogenic stimulus.

Granisetron is approved for pediatric use in certain formulations, but the specific intravenous product should be prescribed according to pediatric dosing guidelines and clinical judgment.

Common side effects include headache, constipation, dizziness, fatigue, diarrhoea, and mild abdominal discomfort.

Serious reactions such as allergic rash, swelling, anaphylaxis, QT‑interval prolongation, severe hypotension, or signs of serotonin syndrome should be evaluated urgently.

Safety data in pregnancy are limited; the medication should only be used if the potential benefit justifies the potential risk to the fetus.

Store the product in a controlled room temperature environment, protected from light, and keep it out of reach of children.

Baseline cardiac assessment, electrolyte levels, and liver or kidney function should be evaluated to identify any contraindications or need for dose adjustment.

Yes, it can be part of a multimodal anti‑emetic regimen, but clinicians should avoid combining it with other 5‑HT3 antagonists and monitor for additive QT‑prolongation effects.

The ATC classification for granisetron is A04AA02, indicating its role as an antiemetic.

Granisetron is not classified as a controlled substance; it is available by prescription only.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT